MaxCyte Inc. (MXCT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

MaxCyte Inc. (MXCT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.80

0.16 (3.45%)

At close: Jan 15, 2025, 3:43 PM

undefined% (undefined)

Bid	4.8
Market Cap	506.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.34
PE Ratio (ttm)	-14.12
Forward PE	n/a
Analyst	Buy

Ask	4.81
Volume	566,204
Avg. Volume (20D)	579,667
Open	4.81
Previous Close	4.64
Day's Range	4.68 - 4.92
52-Week Range	3.17 - 5.32
Beta	undefined

About MXCT

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jul 30, 2021

Employees 143

Stock Exchange NASDAQ

Ticker Symbol MXCT

Website https://maxcyte.com

Analyst Forecast

According to 2 analyst ratings, the average rating for MXCT stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 97.92% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

MaxCyte Inc. is scheduled to release its earnings on Mar 11, 2025, during market hours.
Analysts project revenue of $7.67M, reflecting a -51.04% YoY shrinking and earnings per share of -0.13, making a 160.00% increase YoY.

Why Price Moved

1 day ago · Source

+11.59%

MaxCyte shares are trading higher after the compan... Unlock content with Pro Subscription

1 month ago · Source

+15.83%

MaxCyte shares are trading higher after the company raised its FY24 core revenue guidance and announced layoffs to save $5.8 million per year.

News

2 months ago · seekingalpha.com

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago.

3 months ago · zacks.com

MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?

MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).